Raid Aljumaily to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Raid Aljumaily has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
0.839
-
Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study. Am J Ther. 2018 Nov/Dec; 25(6):e767-e768.
Score: 0.571
-
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. Lung Cancer. 2021 05; 155:151-155.
Score: 0.168
-
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer. Lung Cancer. 2014 Jan; 83(1):67-72.
Score: 0.100